Vertex Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.
Vertex Pharmaceuticals (VRTX) shares rose 3.13% to $441.74 on Thursday, marking its second consecutive day of gains. Despite this daily increase, the stock underperformed relative to competitors like AbbVie and Krystal Biotech during a broader market rally where the S&P 500 and Dow Jones also gained. Trading volume exceeded its 50-day average, though VRTX remains 13.03% below its 52-week high.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: MarketWatch Automated The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments